US-based Becton, Dickinson and Co (BD) has announced seven underwritten public offerings of notes to raise $10.463bn.

The notes carry interest rates of 0.368% (due June 2019), 2.133% (due June 2019), and 2.404% (due June 2020). They also have rates of 2.894% (due June 2022), floating rate (due June 2022), 3.363% (due June 2024), 3.700% (due June 2027), and 4.669% (due June 2047).

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Earlens Corp has announced the private placement of Series C preferred stock in order to raise $73m.

Vertex Healthcare subscribed to the placement along with participation from Cochlear Ltd, CRG, Richard King Mellon Foundation, Windham Venture Partners, and others.

The US-based company plans to use the funds for commercialisation of its Earlens hearing aid, and to support research and development (R&D) activities.

The UK-based biopharmaceutical company AstraZeneca plc has announced three public offerings of senior notes, including floating rate senior notes to raise gross proceeds of $2bn.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The notes bear interest rates of 2.375% and 3.125%, which are due to mature in 2022 and 2027, respectively.

"The US-based company plans to use the funds for commercialisation of its Earlens hearing aid, and to support research and development (R&D) activities."

AstraZeneca plans to use the funds for general corporate purposes.

2bPrecise LLC has signed a technology licensing agreement with non-profit medical research group, Mayo Clinic, to develop genomics-based clinical decision support protocols.

As part of the agreement, 2bPrecise will incorporate the new protocols to measure results in patients affected with cardiovascular genetic disease.

2bPrecise is a provider of cloud-based precision medicine platform and is based in the US.

Trice Medical Inc has announced the raising of $19.3m in a series C venture financing round.

The US-based orthopaedic diagnostics devices developer plans to use the funds to expand its presence in the US market.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
HemoSonics has won the 2025 Marketing Award for its impactful promotion of theQuantra Hemostasis System and leadership in blood management education. See how targeted campaigns, thought leadership content, and hands on clinician training are accelerating Quantra’s market traction and shaping the future of hemostasis testing.

Discover the Impact